AstraZeneca trial failure raises bigger questions about its portfolio
AstraZenecaWainua's failed final trial was never expected to have a major financial impact on the company. Most analysts estimate that…
AstraZenecaWainua's failed final trial was never expected to have a major financial impact on the company. Most analysts estimate that…
AbivaxThe latest round of funding allows the biotech to move toward launching its intestinal disease drug in the United States…
Actions of AstraZeneca fell as much as 9% after a late-stage clinical trial for a heart disease drug failed to…
CNBC's Jim Cramer said Monday that investors should not fear the latest market rotation. Instead, he believes he is creating…
Doctors Without Borders health workers in personal protective equipment move through the isolated red zone to monitor patients, provide medical…
The Food and Drug Administration on Tuesday authorized Philip MorrisZyn's proprietary Zyn nicotine pouches will be marketed as less harmful…
modern Expanding the portfolio beyond infectious diseases is giving investors a new reason to own stocks after years of uncertainty…
A version of this article first appeared in CNBC's Healthy Returns newsletter, bringing the latest healthcare news directly to your…
Shares of a French biotechnology company Abivax surged on Tuesday after it released new data on its lead drug for…
Wegovy weight loss treatment injectable pens, manufactured by Novo Nordisk A/S, on display during a press conference in Mumbai, India,…